Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Nintedanib

Drug and asset intelligence for Nintedanib with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 3
Stage: Development stage unavailable

Sponsor company

Glenmark Pharmaceuticals →

Recent signals(3)

StrategyAugust 8, 2026

FDA Grants Approval for Nintedanib Esylate ANDA219926 by Macleods Pharmaceuticals

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 219926 for Nintedanib Esylate submitted by Macleods Pharmaceuticals.

RegulatoryJuly 15, 2026

FDA Accepts Nintedanib Application from Glenmark Pharmaceuticals

The FDA has accepted the application for Nintedanib (ANDA212555) from Glenmark Pharmaceuticals.

ClinicalJuly 2, 2026

Phase 2 Trial of Nintedanib DPI in Idiopathic Pulmonary Fibrosis Initiated by Mannkind Corporation

Mannkind Corporation is conducting Phase 2 trial of inhaled Nintedanib DPI in patients with IPF, focusing on safety and preliminary efficacy.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(3)

Topline Data

Glenmark Pharmaceuticals — Nintedanib

July 15, 2026 · N/A

Topline Data

— Nintedanib

July 15, 2026 · N/A

Topline Data

— Nintedanib

July 2, 2026 · N/A

Indications

Idiopathic Pulmonary Fibrosis →

Therapeutic areas

Idiopathic Pulmonary Fibrosis →

Oncology · Small Molecule →

Pulmonology →

Pulmonology · Idiopathic Pulmonary Fibrosis →

Small Molecule →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.